This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
Ettinger S, Stanak M, Huić M, Hacek RT, Ercevic D, Grenkovic R, Wild C. Wearable cardioverter-defibrillator (WCD) therapy in primary and secondary prevention of sudden cardiac arrest in patients at risk. Vienna: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBIHTA). Decision Support Document. 2016
This assessment, performed within the "European Network for Health Technology Assessment (EUnetHTA) Joint Action 3, aimed to provide valid data on clinical effectiveness and safety of the WCD. Furthermore, the project intended to elicit patients' views on aspects regarding their cardiac disease and the WCD therapy as well as to identify neglected outcomes.
According to the published data, no statement can be made about the device's effectiveness – further research is needed. Studies suggest that the WCD could be a relatively safe intervention in the short to medium term. However, more data and more adequate reporting of (serious) adverse events are needed in order to establish the device safety. In particular, more data is needed for specific risk stratification of high risk patients in order to further narrow down the wide range of indications for WCD use.
Subject indexing assigned by CRD
Death, Sudden, Cardiac; Defibrillators; Humans; Secondary Prevention
Country of organisation
An English language summary is available.
Address for correspondence
Ludwig Boltzmann Institute fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7 rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99
Date abstract record published